Serina Total Liab vs Capital Lease Obligations Analysis

SER Stock

4.79 0.64 15.42%

Serina Therapeutics financial indicator trend analysis is much more than just breaking down Serina Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Serina Therapeutics is a good investment. Please check the relationship between Serina Therapeutics Total Liab and its Capital Lease Obligations accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Serina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide.

Total Liab vs Capital Lease Obligations

Total Liab vs Capital Lease Obligations Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Serina Therapeutics Total Liab account and Capital Lease Obligations. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Serina Therapeutics' Total Liab and Capital Lease Obligations is -0.35. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Capital Lease Obligations in the same time period over historical financial statements of Serina Therapeutics, assuming nothing else is changed. The correlation between historical values of Serina Therapeutics' Total Liab and Capital Lease Obligations is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Serina Therapeutics are associated (or correlated) with its Capital Lease Obligations. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Lease Obligations has no effect on the direction of Total Liab i.e., Serina Therapeutics' Total Liab and Capital Lease Obligations go up and down completely randomly.

Correlation Coefficient

-0.35

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Capital Lease Obligations

Serina Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Serina Therapeutics asset purchases. For example, Serina Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Serina Therapeutics control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.

Most indicators from Serina Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Serina Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Serina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide.As of 12/18/2024, Selling General Administrative is likely to drop to about 1 M. In addition to that, Issuance Of Capital Stock is likely to drop to 3,781

	2021	2022	2024 (projected)
Total Revenue	3.0M	500K	134.9K
Depreciation And Amortization	131K	132K	124.5K

Total Revenue Depreciation And Amortization

Serina Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Short Term Investments	Capital Lease Obligations	Inventory
Total Assets		0.25	0.31	0.66	0.84	0.18	-0.33	0.06	-0.91	0.76	0.21	0.89	0.3	0.03	0.15	0.39	-0.79	0.23	0.75	-0.76	0.18	0.59	-0.12	-0.24	-0.21	0.29
Short Long Term Debt Total	0.25		0.04	0.77	0.29	-0.44	-0.26	0.91	-0.62	0.66	-0.43	0.38	-0.08	-0.59	-0.04	0.24	-0.34	0.1	0.6	-0.28	-0.31	0.74	0.04	-0.29	-0.3	0.02
Other Current Liab	0.31	0.04		0.48	0.76	0.87	0.78	-0.37	-0.33	-0.17	0.87	-0.12	0.99	0.78	0.99	-0.51	-0.81	0.99	-0.04	-0.85	0.93	-0.31	-0.94	0.72	0.71	0.66
Total Current Liabilities	0.66	0.77	0.48		0.78	0.05	-0.04	0.51	-0.88	0.66	0.08	0.55	0.39	-0.09	0.36	-0.01	-0.8	0.47	0.77	-0.76	0.16	0.6	-0.26	-0.01	-0.03	0.48
Total Stockholder Equity	0.84	0.29	0.76	0.78		0.55	0.19	-0.07	-0.84	0.47	0.57	0.55	0.73	0.39	0.64	-0.01	-0.99	0.71	0.52	-0.99	0.6	0.29	-0.6	0.22	0.24	0.57
Property Plant And Equipment Net	0.18	-0.44	0.87	0.05	0.55		0.82	-0.77	-0.01	-0.46	0.98	-0.28	0.93	0.97	0.9	-0.53	-0.57	0.84	-0.34	-0.63	0.99	-0.62	-0.88	0.78	0.79	0.58
Current Deferred Revenue	-0.33	-0.26	0.78	-0.04	0.19	0.82		-0.54	0.32	-0.73	0.79	-0.71	0.8	0.83	0.87	-0.77	-0.26	0.81	-0.58	-0.33	0.85	-0.77	-0.85	0.89	0.87	0.47
Net Debt	0.06	0.91	-0.37	0.51	-0.07	-0.77	-0.54		-0.41	0.65	-0.77	0.36	-0.49	-0.85	-0.43	0.4	0.04	-0.31	0.54	0.11	-0.67	0.8	0.43	-0.51	-0.52	-0.21
Retained Earnings	-0.91	-0.62	-0.33	-0.88	-0.84	-0.01	0.32	-0.41		-0.86	-0.04	-0.85	-0.27	0.17	-0.17	-0.36	0.82	-0.3	-0.84	0.77	-0.07	-0.76	0.14	0.25	0.23	-0.3
Accounts Payable	0.76	0.66	-0.17	0.66	0.47	-0.46	-0.73	0.65	-0.86		-0.44	0.94	-0.24	-0.6	-0.33	0.69	-0.43	-0.2	0.85	-0.36	-0.42	0.97	0.32	-0.62	-0.58	-0.04
Cash	0.21	-0.43	0.87	0.08	0.57	0.98	0.79	-0.77	-0.04	-0.44		-0.24	0.93	0.95	0.89	-0.55	-0.58	0.82	-0.27	-0.64	0.97	-0.61	-0.84	0.68	0.69	0.49
Non Current Assets Total	0.89	0.38	-0.12	0.55	0.55	-0.28	-0.71	0.36	-0.85	0.94	-0.24		-0.15	-0.4	-0.29	0.66	-0.48	-0.19	0.85	-0.42	-0.28	0.84	0.3	-0.61	-0.57	-0.02
Non Currrent Assets Other	0.3	-0.08	0.99	0.39	0.73	0.93	0.8	-0.49	-0.27	-0.24	0.93	-0.15		0.84	0.98	-0.53	-0.77	0.97	-0.1	-0.82	0.97	-0.39	-0.94	0.73	0.73	0.64
Cash And Short Term Investments	0.03	-0.59	0.78	-0.09	0.39	0.97	0.83	-0.85	0.17	-0.6	0.95	-0.4	0.84		0.82	-0.65	-0.4	0.73	-0.42	-0.47	0.94	-0.75	-0.77	0.81	0.8	0.57
Net Receivables	0.15	-0.04	0.99	0.36	0.64	0.9	0.87	-0.43	-0.17	-0.33	0.89	-0.29	0.98	0.82		-0.6	-0.7	0.99	-0.19	-0.74	0.95	-0.45	-0.96	0.79	0.79	0.64
Common Stock Shares Outstanding	0.39	0.24	-0.51	-0.01	-0.01	-0.53	-0.77	0.4	-0.36	0.69	-0.55	0.66	-0.53	-0.65	-0.6		0.06	-0.49	0.27	0.11	-0.56	0.72	0.42	-0.68	-0.57	-0.48
Non Current Liabilities Total	-0.79	-0.34	-0.81	-0.8	-0.99	-0.57	-0.26	0.04	0.82	-0.43	-0.58	-0.48	-0.77	-0.4	-0.7	0.06		-0.77	-0.48	1.0	-0.63	-0.27	0.65	-0.28	-0.3	-0.59
Other Current Assets	0.23	0.1	0.99	0.47	0.71	0.84	0.81	-0.31	-0.3	-0.2	0.82	-0.19	0.97	0.73	0.99	-0.49	-0.77		-0.11	-0.81	0.91	-0.31	-0.97	0.74	0.75	0.64
Other Stockholder Equity	0.75	0.6	-0.04	0.77	0.52	-0.34	-0.58	0.54	-0.84	0.85	-0.27	0.85	-0.1	-0.42	-0.19	0.27	-0.48	-0.11		-0.42	-0.3	0.79	0.32	-0.54	-0.58	0.1
Total Liab	-0.76	-0.28	-0.85	-0.76	-0.99	-0.63	-0.33	0.11	0.77	-0.36	-0.64	-0.42	-0.82	-0.47	-0.74	0.11	1.0	-0.81	-0.42		-0.69	-0.19	0.7	-0.34	-0.35	-0.61
Total Current Assets	0.18	-0.31	0.93	0.16	0.6	0.99	0.85	-0.67	-0.07	-0.42	0.97	-0.28	0.97	0.94	0.95	-0.56	-0.63	0.91	-0.3	-0.69		-0.57	-0.93	0.81	0.82	0.63
Short Term Debt	0.59	0.74	-0.31	0.6	0.29	-0.62	-0.77	0.8	-0.76	0.97	-0.61	0.84	-0.39	-0.75	-0.45	0.72	-0.27	-0.31	0.79	-0.19	-0.57		0.42	-0.66	-0.62	-0.12
Common Stock	-0.12	0.04	-0.94	-0.26	-0.6	-0.88	-0.85	0.43	0.14	0.32	-0.84	0.3	-0.94	-0.77	-0.96	0.42	0.65	-0.97	0.32	0.7	-0.93	0.42		-0.78	-0.82	-0.54
Short Term Investments	-0.24	-0.29	0.72	-0.01	0.22	0.78	0.89	-0.51	0.25	-0.62	0.68	-0.61	0.73	0.81	0.79	-0.68	-0.28	0.74	-0.54	-0.34	0.81	-0.66	-0.78		0.99	0.75
Capital Lease Obligations	-0.21	-0.3	0.71	-0.03	0.24	0.79	0.87	-0.52	0.23	-0.58	0.69	-0.57	0.73	0.8	0.79	-0.57	-0.3	0.75	-0.58	-0.35	0.82	-0.62	-0.82	0.99		0.71
Inventory	0.29	0.02	0.66	0.48	0.57	0.58	0.47	-0.21	-0.3	-0.04	0.49	-0.02	0.64	0.57	0.64	-0.48	-0.59	0.64	0.1	-0.61	0.63	-0.12	-0.54	0.75	0.71

Click cells to compare fundamentals

Serina Therapeutics Account Relationship Matchups

Pair Trading with Serina Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Serina Stock

0.79	VALN	Valneva SE ADR	Pair Corr
0.62	ERNA	Eterna Therapeutics	Pair Corr

Moving against Serina Stock

0.73	GILD	Gilead Sciences	Pair Corr
0.71	BMY	Bristol Myers Squibb	Pair Corr
0.62	DYAI	Dyadic International	Pair Corr
0.53	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr

The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.

The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Serina Stock Analysis

When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC